In an announcement via Genetic Engineering & Biotechnology News, “Evotec said yesterday it hammered out a definitive agreement for a five-year, minimum-guaranteed €250 million (nearly $270 million) strategic alliance with Sanofi focused on developing multiple products.”  Sanofi’s recent efforts to cut back on internal research and development have inspired the deal with Evotec and as a result, both companies will combine their libraries of small-molecule compounds.